Proud to presenting primary translational results from the @oncodistinct#BrainStorm study at #ESMO25.
CSF ctDNA may serve as a reliable surrogate for CNS mutation profiles, complementing plasma ctDNA profiling.
Thanks to @nuriakb for this opportunity! @JulesBordet@OncoAlert
At #ESMO25@Lucarecco from @JulesBordet presents results from the Brainstorm study
CSF ctDNA in pts with brain and LM metastases had high mutational profile concordance with plasma and only partial overlap with extra-CNS tissue, while also uncovering CNS-specific mut
@OncoAlert
The large and dynamic @JulesBordet family at the @mybsmo Annual meeting at the beautiful city of Bruges 😍 thank you to @E_de_Azambuja & all the organization for such q wonderful Congress!! 🇧🇪
#BSMO25#oncology
The beautiful @JulesBordet family is reunited in Barcelona for the European Society of Medical Oncology annual meeting 2024 #ESMO24! We come back with the updates in oncology and lots of new projects to help our patients 💥🎗
📢#ASCO2024@BlancJeremy presented survival data from AURA trial: Avelumab as neoadjuvant therapy in patients with muscle-invasive urothelial carcinoma at ASCO2024 in Chicago,USA🇺🇸
🫱🏻🫲🏽Many thanks to all those who contributed to this trial.
🆕🔊 First patient was recruited into the COPERNIC trial! A study from the OncoDistinct Network, aiming to evaluate the association between early changes of ctDNA and response to treatment in patients with advanced colorectal cancer. 🙌
#ColorectalCancer#ClinicalTrials#oncology
OncoDistinct Team was at #ESMO2023 🇪🇦
○ Professor Ahmad Awada, one of the creators of this Network
○ Nuria Kotecki, executive officer of the OncoDistinct Network
○ Jacques Medioni, active member of the Network
○ Sofiane Bendiab, project coordinator of the OncoDistinct Network
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.
Correspondence from @nuriakb@JulesBordet and colleagues
https://t.co/P7a5JJASaS
Brain metastases are still one of the biggest challenges in oncology
#BrainStorm is an international platform that gathers clinical, imaging & molecular data to inform better management strategies
Check it out on @NatureMedicine
👉 https://t.co/3uQCGK1qoI
@OncoAlert#bcsm
📍#BrainStorm (NCT04109131), an investigator-initiated prospective #ClinicalStudy recruiting in 🇧🇪🇫🇷🇱🇺 to better understand #epidemio & #biology of 🧠 metastases
🗞 Hot off the press our correspondence to @NatureMedicine explaining design&objectives
👉https://t.co/yO5Rq4ZfIa 🧵
What is the best strategy after CDK4/6 inhibitors for the treatment of HR+ breast cancer?
We need high quality #RWE to address important questions that will not be answered by RCTs
@DMBranco presenting the #ALINE study proposal for the @oncodistinct network
@OncoAlert#bcsm